Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | CA2 | P00918 | 3/20 | 0.62 |
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7435099 | 0.85 | ATM (0.76) | ATMPOLBMAPTKMT2ACA2 | |
| Hydrochloric Acid SCHEMBL11808765 | 0.83 | ATM (0.73) | ATMPOLBMAPTKMT2ACA2 | |
| SCHEMBL557799 | 0.83 | ATM (1.00) | ATMPOLBMAPTKMT2ACA2 | |
| SCHEMBL8635081 | 0.83 | ATM (1.00) | ATMPOLBMAPTKMT2ACA2 | |
| SCHEMBL30230461 | 0.83 | ATM (1.00) | ATMPOLBMAPTKMT2ACA2 | |
| SCHEMBL16641094 | 0.82 | CYP19A1 (0.77) | ATMPOLBMAPTKMT2ACA2 | |
| SCHEMBL31157848 | 0.82 | CYP19A1 (0.77) | ATMPOLBMAPTKMT2ACA2 | |
| Iodide SCHEMBL8828192 | 0.81 | ATM (0.96) | ATMPOLBMAPTKMT2ACA2 | |
| SCHEMBL6966485 | 0.81 | ATM (0.71) | ATMPOLBMAPTKMT2ACA2 | |
| SCHEMBL19026923 | 0.81 | ATM (0.71) | ATMPOLBMAPTKMT2ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692096-B1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARM SPA (IT) | 2013-04-03 | — | — | EP | claimed |
| US-20100197799-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-05 | — | — | US | claimed |
| US-20070049643-A1 | Hydroxylamine derivatives | VICURON PHARMACEUTICALS INC. | 2007-03-01 | — | — | US | claimed |
| EP-1692096-A1 | HYDROXYLAMINE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-23 | — | — | EP | claimed |
| WO-2005058800-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-30 | — | — | WO | claimed |
| EP-1692096-B1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARM SPA (IT) | 2013-04-03 | — | — | EP | disclosed |
| US-20100197799-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-05 | — | — | US | disclosed |
| US-7763751-B2 | Hydroxylamine derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-07-27 | — | — | US | disclosed |
| US-20070049643-A1 | Hydroxylamine derivatives | VICURON PHARMACEUTICALS INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1692096-A1 | HYDROXYLAMINE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005058800-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-30 | — | — | WO | disclosed |
| EP-0538384-A4 | OXAMIDES | SMITHKLINE BEECHAM CORP (US) | 1995-04-12 | — | — | EP | disclosed |
| US-5393788-A | Phenylalkyl oxamides | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0538384-A1 | OXAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992000968-A1 | OXAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197799-A1 | HYDROXYLAMINE DERIVATIVES | C9, C1S, HTT | ATM 4280/4885POLB 4202/4885MAPT 149/4885 |
| US-20070049643-A1 | Hydroxylamine derivatives | C9, C1S, HTT | ATM 4229/4885POLB 4177/4885MAPT 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.